Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
END-1: Carboplatin and Liposomal Doxorubicin in Advanced Endometrial Cancer
NCT00401635Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2002
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and carboplatin in endometrial carcinoma, sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate and Toxicity. Started Nov 2002; status: completed.
02
Drugs
pegylated liposomal doxorubicincarboplatin
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00401635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401635.